Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476)

作者:James N; de Bono J; Spears M R; Clarke N W; Mason M D; Dearnaley D; Ritchie A W S; Russell M; Gilson C; Jones R; Gillessen S; Matheson D; Aung S; Birtle A; Chowdhury S; Gale J; Malik Z; O'Sullivan J; Parmar M K; Sydes M R
来源:42nd European-Society-for-Medical-Oncology Congress (ESMO), 2017-09-08 to 2017-09-12.
  • 出版日期2017-9